Stock LOVE CANNARA BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Cannara Biotech Inc. Stock Canadian Securities Exchange

Equities

LOVE

CA13765U1012

Healthcare Facilities & Services

Delayed Canadian Securities Exchange
Other stock markets
 		5-day change 1st Jan Change
- CAD -.--% Intraday chart for Cannara Biotech Inc. -.--% +87.50%
Jan. 29 Cannara Biotech Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023 CI
2023 Cannara Biotech Inc. Reports Earnings Results for the Full Year Ended August 31, 2023 CI

Financials

Sales 2022 35.84M 26.05M Sales 2023 57.26M 41.62M Capitalization 90.41M 65.72M
Net income 2022 2M 1.45M Net income 2023 6M 4.36M EV / Sales 2022 4.32 x
Net Debt 2022 36.28M 26.37M Net Debt 2023 41.51M 30.18M EV / Sales 2023 2.3 x
P/E ratio 2022
135 x
P/E ratio 2023
12.9 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 50.58%
More Fundamentals * Assessed data

Chart Cannara Biotech Inc.

Dynamic Chart

Latest news about Cannara Biotech Inc.

Cannara Biotech Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023 CI
Cannara Biotech Inc. Reports Earnings Results for the Full Year Ended August 31, 2023 CI
Cannara Biotech's Fiscal Q4 Profit, Revenue Grows; Up 9.4% MT
Cannara Biotech Inc. Reports Earnings Results for the Fourth Quarter Ended August 31, 2023 CI
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022. CI
Cannara Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023 CI
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022. CI
Cannara Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023 CI
Cannara Biotech Down Near 8% As Enters into an Automatic Share Purchase Plan MT
Cannara Biotech Converts CA$5 Million Debenture, Plus Interest, into Nearly 30 Million Shares for Olymbec Investments MT
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022. CI
Cannara Biotech Inc. Reports Earnings Results for the First Quarter Ended November 30, 2022 CI
Cannara Biotech Reports Normal Course Issuer Bid for Common Shares MT
Cannara Biotech Inc. announces an Equity Buyback for 15,000,000 shares, representing 1.71% of its issued share capital. CI
Toronto Stocks Rise, Cannara Biotech Shares Climb on 4Q Results DJ
More news

Press releases Cannara Biotech Inc.

Cannara Biotech CFO Nicholas Sosiak: Unveiling Success Strategies and Future Plans AQ
Cannara Biotech to Host Investor Webcast on Thursday December 14th, 2023 AQ
Cannara Biotech Inc. Reports Record Q3 2023 Financial Results with Net Revenues of $15.9 Million and Net Income of $2.9 million PR
Cannara Biotech Inc Announces Participation in the LD Micro Invitational XIII NE
Cannara Biotech Inc. Enters into an Automatic Share Purchase Plan PR
More press releases

Managers and Directors - Cannara Biotech Inc.

Managers TitleAgeSince
Zohar Krivorot CEO
 Chief Executive Officer 48 18-12-30
Nicholas Sosiak DFI
 Director of Finance/CFO - 19-03-31
Avi Krivorot CTO
 Chief Tech/Sci/R&D Officer - 21-03-31
Members of the board TitleAgeSince
Jacob M. Kay BRD
 Director/Board Member 83 19-05-24
Donald Olds BRD
 Director/Board Member 64 20-11-09
Zohar Krivorot CEO
 Chief Executive Officer 48 18-12-30
More insiders

Company Profile

Cannara Biotech Inc. is a Canada-based vertically integrated producer of premium-grade cannabis and cannabis-derivative products for the Quebec and Canadian markets. It operates through its wholly owned subsidiaries, Cannara Biotech (Quebec) Inc. and Cannara Biotech (Valleyfield) Inc. The Company owns two mega facilities based in Quebec spanning over 1,650,000 square feet, providing the Company with 100,000 kilograms of annualized cultivation output. It operates in two segments: Cannabis operations and Real estate operations. The Cannabis operations, which encompasses the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and other cannabis services (Cannabis operations). The Real estate operations, related to the Farnham and Valleyfield building (Real estate operations). The Company’s brand portfolio includes Tribal, Nugz, and Orchid CBD. Orchid CBD is a wellness brand that provides premium CBD-dominant cannabis.
Sector
Healthcare Facilities & Services
Calendar
2024-04-23 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Medical Farming

1st Jan change Capi.
ASCEND WELLNESS HOLDINGS, INC. Stock Ascend Wellness Holdings, Inc.
+31.96% 276M
AYR WELLNESS INC. Stock Ayr Wellness Inc.
+31.69% 272M
ORGANIGRAM HOLDINGS INC. Stock Organigram Holdings Inc.
+51.74% 195M
THE CANNABIST COMPANY HOLDINGS INC. Stock The Cannabist Company Holdings Inc.
-37.68% 141M
JUSHI HOLDINGS INC. Stock Jushi Holdings Inc.
+38.26% 133M
INTERCURE LTD. Stock InterCure Ltd.
+100.82% 112M
IANTHUS CAPITAL HOLDINGS, INC. Stock iAnthus Capital Holdings, Inc.
-28.57% 96.23M
4FRONT VENTURES CORP. Stock 4Front Ventures Corp.
+3.85% 93.09M
BAKHU HOLDINGS, CORP. Stock Bakhu Holdings, Corp.
+150.00% 75.33M
Medical Farming
  1. Stock Market
  2. Equities
  3. LOVE Stock
  4. LOVE Stock